0000000000670776

AUTHOR

A. Calascibetta

showing 9 related works from this author

Relationship Between Thymidylate Synthase and p53 and Response to FEC Versus Taxane Adjuvant Chemotherapy for Breast Carcinoma

2011

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients wit…

Bridged-Ring CompoundsOncologymedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentBreast NeoplasmsThymidylate synthaseBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAdjuvant therapyHumansPharmacology (medical)CyclophosphamideEpirubicinNeoplasm StagingPharmacologyChemotherapyTaxanebiologybusiness.industryThymidylate SynthasePrognosismedicine.diseaseImmunohistochemistryInfectious DiseasesOncologyChemotherapy AdjuvantFluorouracilbiology.proteinCancer researchFemaleTaxoidsFluorouracilTumor Suppressor Protein p53businessmedicine.drugEpirubicinJournal of Chemotherapy
researchProduct

Thymidylate synthase polymorphism and microsatellite instability: association in colorectal cancer.

2005

5-Fluorouracil (5FU) is the main drug used for the treatment of colorectal cancer (CRC) and Thymidilate Synthase (TS) is its target enzyme. TS gene has regulatory tandemly repeated sequences in its 5'' and 3''untraslated region (5''-3'' UTR). CRC often shows a kind of genomic instability called Microsatellite Instability (MSI) that is associated with TS levels and survival. Our data show that the genotype 2R/2R (homozygosity for 2 tandem repeat sequences in the 5''UTR) is more frequently associated with MSI+ and lower TS levels. More over we did not find any significant association between the 2R/3R (heterozygosity for 2 and 3 tandem repeat sequences in the 5''UTR) and 3R/3R (homozygosity f…

Untranslated regionGenome instabilityHeterozygoteGenotypeTranscription GeneticColorectal cancerBiologyBiochemistryThymidylate synthaseLoss of heterozygosityCell Line TumorGenotypeGeneticsmedicineHumansRNA MessengerneoplasmsGeneGeneticsPolymorphism GeneticChemistryMicrosatellite instabilityHeterozygote advantageGeneral MedicineThymidylate Synthasemedicine.diseaseMolecular biologydigestive system diseasesPhenotypeDrug Resistance NeoplasmProtein Biosynthesisbiology.proteinMolecular MedicineColorectal NeoplasmsMicrosatellite RepeatsNucleosides, nucleotidesnucleic acids
researchProduct

Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophsphamide, methotrexate, 5-fluorouracil chemotherapy …

2006

10546 Background: Adjuvant chemotherapy is used in the treatment of breast carcinoma independently of axillar node involvement. Different drug combinations such as CMF, FAC, FEC are still used; recently new drugs such as TXT (NEJM 332:1004,1997) show activity and are used also in adjuvant chemotherapy. 5 Fluorouracil (5Fu), a drug involved in main therapeutic regimens, blocks Thymidylate Synthase (TS), an enzyme involved in the DNA synthesis. TS not only links its own mRNA, but also p53 mRNA, inhibiting post transcriptional p53 protein synthesis. TS protein overexpression (Cancer Res 55:1407,1995), and/or its absence (Cancer Res 61:1421,2001) are some of the main mechanisms of 5-Fu drug re…

OncologyCancer ResearchChemotherapymedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentCyclophosphamide/methotrexateLocally advancedmedicine.diseaseThymidylate synthaseOncologyDocetaxelFluorouracilInternal medicineCarcinomamedicinebiology.proteinBreast carcinomabusinessmedicine.drug
researchProduct

Matrix metalloproteinase-1 is differentially expressed in signet ring cell, and intestinal colorectal carcinomas histotypes

2007

14564 Background: Signet ring cell colorectal carcinoma ( SRCC) pure is an infrequent and highly malignant variant of colorectal cancer, while this histological component is present in 30% of all colorectal carcinomas. In our previous studies we compared the E- Cadherin, β- Catenin, Fibronectin, Ki 67 and Thymidylate Synthase (TS) expression of SRCC, the intestinal type of colorectal carcinoma (ICRC) to try to explain the pathogenesis, the aggressiveness and the low 5 Fluorouracil (5FU) responsiveness of these tumours. We found that all SRCCs had very low levels of all markers and were in the post- mitotic phase of the cell cycle. To understand their high metastatic capability we assessed …

OncologyCancer Researchmedicine.medical_specialtyOncologybusiness.industrySignet ring cellColorectal cancerInternal medicinemedicineCancer researchMatrix metalloproteinasebusinessmedicine.diseaseJournal of Clinical Oncology
researchProduct

Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.

2005

Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified. To date an accurate evaluation of predictive markers is mainly done at the primary site; however, the main goal of adjuvant therapy for breast cancer is the control of micrometastases. The aim of this study is to assess as therapeutic and/or prognostic marker, the proliferation status of primary tumors and involved nodes as measured by Ki67 and thymidylate synthase (TS) expression, in 30 breast cancer node positive patients. TS is the main target of 5-fluorouracil (5-FU) activity, and its overexpression is one of the mechanisms of 5-FU drug resistance; however, in some studies its a…

CA15-3Antimetabolites AntineoplasticProliferation indexBreast NeoplasmsDiseaseDrug resistanceBiologySettore MED/08 - Anatomia PatologicaBiochemistryThymidylate synthaseGene Expression Regulation EnzymologicBreast cancerbreast cancerAntigens NeoplasmGeneticsmedicineAdjuvant therapyHumansNeoplasm MetastasisCell ProliferationGeneral MedicineThymidylate SynthaseCell cyclemedicine.diseasePrognosisGene Expression Regulation NeoplasticKi-67 AntigenmetastaseLymphatic MetastasisImmunologyCancer researchbiology.proteinMolecular MedicineFemaleFluorouracilKi67Nucleosides, nucleotidesnucleic acids
researchProduct

Analysis of the Thymidylate Synthase Gene Structure in Colorectal Cancer Patients and Its Possible Relation with the 5-Fluorouracil Drug Response

2009

Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and it is the target for the 5-Fluorouracil (5-FU) activity. Barbour et al. showed that variant structural forms of TS in tumour cell lines confer resistance to fluoropyrimidines. We planned to perform the whole TS gene structure by means of sequencing techniques in human colorectal cancer (CRC) samples to try to identify the presence of any possible TS variant form that could be responsible of fluoropyrimidines drug resistance and of the worse prognosis. We performed the TS-DNA gene sequence in 68 CRC from patients of A, B, and C Dukes' stages and different histological grade, but we did not find any mutation in the TS-DNA str…

Genome instabilityArticle Subjectlcsh:QH426-470Colorectal cancerDrug resistancemedicine.disease_causeBioinformaticsBiochemistryThymidylate synthaselcsh:Biochemistrymedicinelcsh:QD415-436Molecular BiologyGeneMutationbiologybusiness.industryMethylationmedicine.diseaselcsh:GeneticsFluorouracilbiology.proteinCancer researchbusinessResearch Articlemedicine.drugJournal of Nucleic Acids
researchProduct

Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma

2004

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyProliferation indexColorectal cancerSettore MED/08 - Anatomia PatologicaThymidylate synthase expressionThymidylate synthaseSignet ring cell carcinomaSignet ring cell carcinomaCarcinomamedicineHumansThymidylate synthase expression; Signet ring cell carcinoma; Colorectal carcinoma; ImmunohistochemistryAgedbiologySignet ring cellThymidylate SynthaseMiddle AgedCell cyclemedicine.diseaseImmunohistochemistrydigestive system diseasesNeoplasm ProteinsColorectal carcinomaKi-67 AntigenOncologybiology.proteinCancer researchSettore BIO/14 - FarmacologiaImmunohistochemistryFemaleColorectal NeoplasmsCarcinoma Signet Ring Cell
researchProduct

Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer

2005

Abstract BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by…

AdultAged 80 and overMalePolymorphism GeneticAntibodies MonoclonalThymidylate SynthaseMiddle AgedSettore MED/08 - Anatomia PatologicaImmunohistochemistryGenomic InstabilityHumansFemaleColorectal cancer thymidylate synthase pharmacogenomic microsatellite instability polymorphism molecular therapeutic.RNA Messenger5' Untranslated RegionsColorectal NeoplasmsPromoter Regions GeneticAgedMicrosatellite Repeats
researchProduct

Different expression of thymidylate synthase in primary tumour and metastatic nodes in breast cancer patients.

2007

BACKGROUND: To date an accurate evaluation of predictive markers in breast cancer is mainly conducted at the primary site, although the main goal of the adjuvant therapy is the control of micrometastases. Adjuvant therapy drugs need a high proliferative cell rate to be effective. The proliferating activity can be evaluated by the Ki-67 marker and even by thymidylate synthase (TS), a cell cycle enzyme present in proliferating cells. In this study the TS levels in primary tumours were compared to those of their metastases. PATIENTS AND METHODS: The TS expression and Ki-67 were evaluated by means of immunohistochemistry in 80 primary breast tumours (PTs) and in their matched axillary metastati…

AdultKi-67 AntigenLymphatic MetastasisHumansBreast cancer thymidylate synthase Mib-1/Ki-67 metastatic lymph nodes.Breast NeoplasmsFemaleCell Growth ProcessesThymidylate SynthaseSettore MED/08 - Anatomia PatologicaImmunohistochemistryNeoplasm StagingAnticancer research
researchProduct